---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-25-019829"
form_type: "8-K"
ticker: "BIAF"
cik: "0001712762"
company_name: "bioAffinity Technologies, Inc."
filed_at: "2025-10-28T23:59:59+00:00"
generated_at: "2026-05-17T01:57:23.133243+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# bioAffinity Technologies announces Australian patent acceptance for lung health platform

## Summary
- IP Australia accepted patent application AU 2019253111 for a flow cytometry-based platform to detect multiple lung diseases.
- The patent covers methods using fluorescent probes to identify cellular signatures of lung disease in sputum samples.
- Patent will be automatically issued in three months unless a third party files an opposition.
- Company now holds 18 awarded and 33 pending patents globally, including in the U.S., China, Japan, and Europe.
- The technology underpins CyPath® Lung, the company's noninvasive test for early-stage lung cancer.

## SEC filing metadata
- accession: 0001493152-25-019829
- form_type: 8-K
- ticker: BIAF
- cik: 0001712762
- company_name: bioAffinity Technologies, Inc.
- filed_at: 2025-10-28T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1712762/000149315225019829/0001493152-25-019829-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1712762/000149315225019829/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-25-019829
- JSON: https://secwatch.observer/filing/0001493152-25-019829.json
- Plain text: https://secwatch.observer/filing/0001493152-25-019829.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.